Novo Nordisk (NVO) announced that the U.S. FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events such as cardiovascular death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they’ve had a prior CV event or not. Results of the SOUL trial reinforce the clinical profile of the semaglutide molecule, which has been studied across a variety of therapeutic areas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Midday Fly By: Apple new F1 broadcast partner, CSX reports Q3 beat
- Casual Dining Stocks: Feeling Down in the Mouth as Festive Economy Freezes
- Novo Nordisk (NVO) and Eli Lilly (LLY): Weight-Loss Drug Stocks Dip on Trump’s New Price Promise
- Eli Lilly falls after Trump says negotiating lower GLP-1 prices
- Trump says cost of GLP-1 drugs to come down ‘pretty fast’, Bloomberg says